A real-world study of irinotecan hydrochloride liposome injection II in pancreatic cancer patients in China

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400082945

Enrollment

Unknown

Registered

2024-04-11

Start date

2024-04-11

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

Interventions

Prospective cohort:None

Retrospective cohort:None

Eligibility

Sex/Gender

All

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging; 2. Age =18 years old, male or female; 3. Patients receiving treatment based on irinotecan hydrochloride liposome injection II; 4. The subjects voluntarily joined the study and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Confirmed pregnant or lactating women; 2. The researchers determined that other conditions were not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
TEAE;	—

Secondary

Measure	Time frame
oveeall survival;rwPFS;rwORR;rwDoT;	—

Countries

China

Contacts

Public ContactLiwei Wang; Taiping Zhang

Renji Hospital Peking Union Medical College Hospital

andrewzhangt@aliyun.com+86 135 2013 2976

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026